Late clinical stage company founded in 2010 focused on the discovery and development of drugs for the treatments of rare disorders of the
Central Nervous System (CNS)
Central Nervous System (CNS)
SOMAIPRO®
Proprietary Artificial Intelligence platform that demonstrated a high clinical predictivity with two products in Phase2
Proprietary Artificial Intelligence platform that demonstrated a high clinical predictivity with two products in Phase2
Lead product successfully completed Phase 2b in Huntington’s Disease patients with chorea, suited for the treatment of movement disorders and psychiatric disorders
STANDARD DRUG DISCOVERY AND DEVELOPMENT
$1 to $2 billion
cost of developing a new drug
10 to 15 years
to develop a new drug
90%
of new chemical entities fail before they even reach the clinics
WE CAN REDUCE THOSE NUMBERS TO
$250k to $50M
cost of developing a new drug
4 to 5 years
to develop a new drug
OUR APPROACH
Leveraging the power of Artificial Intelligence
Focused on orphan diseases
Repurposing drugs for new therapeutic indications
PROPRIETARY PIPELINE
7 000
Only 5% have approved treatments
The main focus of our pipeline
are Orphan diseases with a
high unmet medical need
Learn about our pipelinePARTNERSHIP
Workflow adapted to your needs
Learn how you can work with usOur business model is a combination of in-house development and external collaborations. We have entered into multiple industry partnerships, as well as academic collaborations
OUR PERFORMANCE INDICATORS
77%
of our starting programs revealed positive hits that were confirmed at the laboratory bench and that were patentable
27%
of those hits are in preclinical or clincial development
20%
of those preclinical or clinical programs have clinical stage Phase 2 positive results
WE COOPERATE WITH
SOM BIOTECH IN THE MEDIA
LATEST NEWS
SOM Biotech will attend Bio-Neuroscience Conference from February 25th to February 27th 2025
SOM Biotech announces the presentation of the Phase2b study results
SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating a unique profile with robust improvements of chorea in Huntington's Disease Patients and a safe profile with no somnolence, no akathisia and no impact on depression, suicidality or cognition. Read More
SOM Biotech will attend JP Morgan Healthcare Conference from January 13th to January 16th 2025
SOM Biotech participated in the last edition of Barcelona New Economy Week (BNEW)
Created in 2020, the BNEW (BNEW Barcelona) is a physical and digital B2B event focused on unique events to expand the new economy in Barcelona. Dr. Raúl Insa was invited to pitch at the Health panel entitled “New Generation Drugs; Innovation in a Pill” that took place at DFactory Barcelona last October 9th 2024. The…
SOM Biotech announces the presentation of the Phase2b study results in Huntington Chorea Patients at the HDG Conference in Cincinnati
Read More
SOM Biotech announces the database lock of its Phase2b study with SOM3355 in Huntington’s chorea patients and looks for top-line results in August.
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, is pleased to announce the database lock of the Phase 2b study SOMCT03 with SOM3355 for the treatment of chorea in Huntington’s Disease. Press Release